References
Awad MM et al (2013) Acquired resistance to crizotinib from a mutation in CD74–ROS1. N Engl J Med 368:2395–2401. doi:10.1056/NEJMoa1215530
Bergethon K et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870. doi:10.1200/JCO.2011.35.6345
Chen QY, Xu W, Jiao DM, Wu LJ, Song J, Yan J, Shi JG (2013) Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro. Mol Cell Biochem 377:207–218. doi:10.1007/s11010-013-1586-x
Davies KD et al (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570–4579. doi:10.1158/1078-0432.CCR-12-0550
Jin T et al (2014) Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. BMC Cancer 14:191. doi:10.1186/1471-2407-14-191
Acknowledgments
Grant from Shanghai Hospital Development Center (Grant No. SHDC12012308). Grant from Health and Family Planning Commission of Shanghai Municipality (Grant No. 2013ZYJB0301). The authors thanked Yuanshan Fu for language proof-reading.
Conflict of interest
We declare that no benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. We also declare that we have no conflict of interest in connection with this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, H., Pan, Y., Wang, R. et al. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR–ROS1 fusion. J Cancer Res Clin Oncol 141, 185–187 (2015). https://doi.org/10.1007/s00432-014-1821-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1821-1